Entyvio(vedolizumab)
Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Entyvio
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Vedolizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Entyvio | vedolizumab | Takeda | N-125476 RX | 2014-05-20 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| entyvio | Biologic Licensing Application | 2020-11-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| crohn disease | EFO_0000384 | D003424 | K50 |
| enteritis | — | D004751 | K52.9 |
| ulcerative colitis | EFO_0000729 | D003093 | K51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3380 | Injection, vedolizumab, 1 mg |
Clinical
Clinical Trials
97 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 3 | 6 | 12 | 12 | 10 | 43 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 3 | 7 | 11 | 12 | 6 | 39 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | 1 | 2 | 6 | 10 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | — | 1 | — | 1 |
| Pouchitis | D019449 | EFO_0003921 | K91.850 | — | — | — | 1 | — | 1 |
| Self efficacy | D020377 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | — | 1 | — | — | 1 |
| Myelodysplastic syndromes | D009190 | D46 | — | — | 1 | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | — | 1 | — | — | 1 | |
| Biphenotypic leukemia acute | D015456 | C95.0 | — | — | 1 | — | — | 1 | |
| Myelomonocytic leukemia juvenile | D054429 | C93.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 3 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | 2 | 2 | — | — | — | 2 | ||
| Melanoma | D008545 | 2 | 1 | — | — | — | 2 | ||
| Colitis | D003092 | EFO_0003872 | K52.9 | 2 | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | C34.90 | 1 | 1 | — | — | — | 1 | |
| Celiac disease | D002446 | EFO_0001060 | K90.0 | — | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | D89.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Diet therapy | D004035 | 1 | — | — | — | — | 1 | ||
| Hiv | D006678 | O98.7 | 1 | — | — | — | — | 1 | |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutics | D013812 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VEDOLIZUMAB |
| INN | vedolizumab |
| Description | Vedolizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 943609-66-3 |
| RxCUI | 1538097 |
| ChEMBL ID | CHEMBL1743087 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09033 |
| UNII ID | 9RV78Q2002 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Entyvio - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,962 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,502 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more